Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
SpaceX Stock Price Continues to Slide, Musk's Net Worth Falls Below $900 Billion

SpaceX Stock Price Continues to Slide, Musk's Net Worth Falls Below $900 Billion

BlockBeatsBlockBeats2026/07/13 16:24

BlockBeats News, July 14th - Influenced by the continuous decline in SpaceX's stock price, Musk's net worth fell below $90 billion on Monday. SpaceX's stock price dropped 3.8% on Monday to nearly $140, close to its $135 IPO price; Tesla's stock price also fell by 3% during the same period. This round of correction caused Musk's net worth to plunge by $37.9 billion, with his latest net worth at $87.93 billion.


Despite the wealth shrinkage, Musk remains the world's richest person, surpassing Google co-founder Larry Page ($290.1 billion) and Sergey Brin ($267.6 billion). Musk holds 4.8 billion shares of SpaceX and 350 million stock options, as well as approximately 700 million shares of Tesla.


Musk's peak net worth was $1.45 trillion, reached on June 16th when SpaceX's stock price hit a historical high above $225. Since then, the stock has fallen by more than 38%.


Despite the weak stock performance, Wall Street analysts are generally bullish on SpaceX. Raymond James has set a target price of $800, implying a market value of over $10 trillion. According to FactSet data, the average analyst target price is $236, with Arete Research at $401, Morgan Stanley at $300, and Goldman Sachs at $205. Raymond James analyst Brian Gesuale believes that SpaceX is "building the foundational platform for the industrial capacity of the next generation."

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas

A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

智通财经2026/09/14 00:46
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas